Teclison Ltd. has raised $5.9 million to support further development of its lead candidate, TEC-001, an agent designed to induce tumor necrosis and enhance immune checkpoint inhibitors in solid cancers with liver metastasis. Wtt Investment Ltd., the Taiwan-based family office of the late Taiwanese banker Tsai Wan-tsai, led the financing.